Rodrigues M L, Carter P, Wirth C, Mullins S, Lee A, Blackburn B K
Department of Cell Genetics, Genentech Inc., South San Francisco, CA 94080-4990, USA.
Chem Biol. 1995 Apr;2(4):223-7. doi: 10.1016/1074-5521(95)90272-4.
Enzyme-activatable prodrugs in conjunction with antibody-enzyme fusion proteins may enhance the anti-tumor efficacy of antibodies and reduce the toxic side effects of conventional chemotherapeutics. Cephalosporins have proven to be highly versatile triggers for the enzymatic activation of such prodrugs.
A cephem prodrug of taxol (PROTAX) was synthesized by substituting the C-3' position of cephalothin with 2'-(gamma-aminobutyryl) taxol. Hydrolysis of PROTAX by beta-lactamase rapidly released 2'-(gamma-aminobutyryl) taxol (kcat/K(M) = (1.4 +/- 0.1) x 10(5) s-1 M-1), which yielded taxol following intramolecular displacement. PROTAX is inactive in a microtubule assembly assay in vitro but has similar activity to taxol following prolonged activation with beta-lactamase. PROTAX is approximately 10-fold less toxic than taxol against SK-BR-3 breast tumor cells in vitro but has activity approaching that of taxol following prolonged activation with a fusion protein comprising beta-lactamase fused to a tumor-targeting antibody fragment.
Tubulin polymerization activity is abolished and cytotoxicity is reduced in the PROTAX prodrug compared to taxol. Activation of PROTAX by beta-lactamase followed by self-immolation restores the activity of PROTAX to that of free taxol.
酶激活前药与抗体 - 酶融合蛋白联合使用可能会增强抗体的抗肿瘤疗效,并降低传统化疗药物的毒副作用。头孢菌素已被证明是此类前药酶促激活的高度通用触发剂。
通过用2'-(γ-氨基丁酰基)紫杉醇取代头孢噻吩的C-3'位合成了紫杉醇的头孢烯前药(PROTAX)。β-内酰胺酶对PROTAX的水解迅速释放出2'-(γ-氨基丁酰基)紫杉醇(kcat/K(M) = (1.4 ± 0.1) x 10(5) s-1 M-1),其在分子内取代后产生紫杉醇。PROTAX在体外微管组装试验中无活性,但在用β-内酰胺酶长时间激活后具有与紫杉醇相似的活性。在体外,PROTAX对SK-BR-3乳腺肿瘤细胞的毒性比紫杉醇低约10倍,但在用包含与肿瘤靶向抗体片段融合的β-内酰胺酶的融合蛋白长时间激活后,其活性接近紫杉醇。
与紫杉醇相比,PROTAX前药的微管蛋白聚合活性被消除,细胞毒性降低。β-内酰胺酶激活PROTAX后再经自身裂解将PROTAX的活性恢复至游离紫杉醇的活性。